Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 3/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | UPP1 | Q16831 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9908703 | 1.00 | RNASE1 (0.42) | RNASE1BCHECHRM2CHRM4CHRM1 | |
| SCHEMBL767866 | 0.93 | RNASE1 (0.44) | RNASE1BCHECHRM2CHRM4CHRM1 | |
| SCHEMBL9908701 | 0.93 | RNASE1 (0.44) | RNASE1BCHECHRM2CHRM4CHRM1 | |
| SCHEMBL767835 | 0.86 | LGALS9 (0.40) | RNASE1BCHECHRM2CHRM4CHRM1 | |
| SCHEMBL9908698 | 0.86 | LGALS9 (0.40) | RNASE1BCHECHRM2CHRM4CHRM1 | |
| SCHEMBL15216170 | 0.81 | RNASE1 (0.40) | RNASE1BCHECHRM2CHRM4CHRM1 | |
| SCHEMBL15216169 | 0.81 | RNASE1 (0.40) | RNASE1BCHECHRM2CHRM4CHRM1 | |
| SCHEMBL18271850 | 0.81 | RNASE1 (0.53) | RNASE1BCHECHRM2CHRM4CHRM1 | |
| SCHEMBL12222436 | 0.79 | RNASE1 (0.45) | RNASE1BCHECHRM2CHRM4CHRM1 | |
| SCHEMBL9908699 | 0.79 | BCHE (0.37) | RNASE1BCHEPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170107511-A1 | OLIGONUCLEOTIDE END CAPS | BANK OF AMERICA, N.A. | 2017-04-20 | — | — | US | disclosed |
| US-20160348110-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS INC (US) | 2016-12-01 | — | — | US | disclosed |
| US-9453043-B2 | Nucleic acid chemical modifications | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150210733-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | BANK OF AMERICA, N.A. | 2015-07-30 | — | — | US | disclosed |
| US-8975389-B2 | Nucleic acid chemical modifications | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20120071641-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210733-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | NSUN2, RNMT, NSUN3 | RNASE1 6/4885BCHE 4157/4885CHRM2 4712/4885 |
| US-20120071641-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | NSUN2, RNMT, NSUN3 | RNASE1 5/4885BCHE 4250/4885CHRM2 4724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.